190 related articles for article (PubMed ID: 37737075)
1. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
Simon V; Viswam A; Alexander PS; James E; Sudhindran S
Indian J Pharmacol; 2023; 55(4):229-236. PubMed ID: 37737075
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
4. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ; Falagas ME
Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
[TBL] [Abstract][Full Text] [Related]
5. A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria.
Yu LL; Shi XP; Huang JF; Gong Y; Cui CX; Wang T
J Clin Pharm Ther; 2022 Oct; 47(10):1563-1569. PubMed ID: 35670240
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series.
Trifi A; Abdellatif S; Daly F; Mahjoub K; Nasri R; Oueslati M; Mannai R; Bouzidi M; Ben Lakhal S
Chemotherapy; 2016; 61(4):190-6. PubMed ID: 26863534
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
8. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
[TBL] [Abstract][Full Text] [Related]
11. Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study.
Zhang Y; Dong R; Huang Y; Ling X; Ye Z; Jiang S
Int J Antimicrob Agents; 2024 Jan; 63(1):107031. PubMed ID: 37951480
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections.
Wu XL; Long WM; Lu Q; Teng XQ; Qi TT; Qu Q; He GF; Qu J
Front Pharmacol; 2022; 13():672543. PubMed ID: 35571125
[TBL] [Abstract][Full Text] [Related]
15. Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes.
Thammathiwat T; Tiranathanagul K; Srisawat N; Susantitaphong P; Praditpornsilpa K; Eiam-Ong S
Nephrology (Carlton); 2020 Jan; 25(1):32-39. PubMed ID: 31509307
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
[TBL] [Abstract][Full Text] [Related]
17. Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function.
Zheng G; Cai J; Zhou S; Du N; Bai H; He J; Bian X
Per Med; 2022 Jul; 19(4):307-314. PubMed ID: 35762314
[No Abstract] [Full Text] [Related]
18. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
[TBL] [Abstract][Full Text] [Related]
19. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
Pike M; Saltiel E
J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156
[TBL] [Abstract][Full Text] [Related]
20. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.
Dalfino L; Puntillo F; Mosca A; Monno R; Spada ML; Coppolecchia S; Miragliotta G; Bruno F; Brienza N
Clin Infect Dis; 2012 Jun; 54(12):1720-6. PubMed ID: 22423120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
